POS0614 PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS
Fautrel, B., Bouhnik, Y., Dougados, M., Freudensprung, U., Addison, J.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article
Efficacy and safety of fumaric acid esters in young patients aged 10–17 years with moderate‐to‐severe plaque psoriasis: a randomized, double‐blinded, placebo‐controlled trial
Hamm, H., Wilsmann‐Theis, D., Tsianakas, A., Gambichler, T., Taipale, K., Lauterbach, J., Freudensprung, U., Makepeace, C.
Published in British journal of dermatology (1951) (01.07.2021)
Published in British journal of dermatology (1951) (01.07.2021)
Get full text
Journal Article
Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma
Bateman, E.D, Linnhof, A.E, Homik, L, Freudensprung, U, Smau, L, Engelstätter, R
Published in Pulmonary pharmacology & therapeutics (01.01.2008)
Published in Pulmonary pharmacology & therapeutics (01.01.2008)
Get full text
Journal Article
AB0204 THE PROPER STUDY: INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS
Müller-Ladner, U., Gaffney, K., Jadon, D., Freudensprung, U., Addison, J.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article
AB0348 THE PROPER STUDY: A 48-WEEK ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS
Müller-Ladner, U., Gaffney, K., Jadon, D., Matucci-Cerinic, M., Chamizo Carmona, E., Freudensprung, U., Addison, J.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
Dignass, A, Gisbert, J, Freudensprung, U, Addison, J
Published in Journal of Crohn's and colitis (27.05.2021)
Published in Journal of Crohn's and colitis (27.05.2021)
Get full text
Journal Article
AB0311 THE PROPER STUDY: RESULTS OF THE FIRST INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS
Müller-Ladner, U., Gaffney, K., Jadon, D., Freudensprung, U., Addison, J.
Published in Annals of the rheumatic diseases (01.06.2020)
Published in Annals of the rheumatic diseases (01.06.2020)
Get full text
Journal Article
THU0164 PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAIIVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; AN INTERIM ANALYSIS
Fautrel, B., Bouhnik, Y., Desjeux, G., Brigui, A., Freudensprung, U., Addison, J.
Published in Annals of the rheumatic diseases (01.06.2020)
Published in Annals of the rheumatic diseases (01.06.2020)
Get full text
Journal Article
P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
Dignass, A U, Gisbert, J P, Bossa, F, Freudensprung, U, Addison, J
Published in Journal of Crohn's and colitis (21.01.2022)
Published in Journal of Crohn's and colitis (21.01.2022)
Get full text
Journal Article
P585 IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective
Young, D, Latter, S, Harvey, J, Addison, J, Freudensprung, U, Cummings, F
Published in Journal of Crohn's and colitis (27.05.2021)
Published in Journal of Crohn's and colitis (27.05.2021)
Get full text
Journal Article
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis
Selmi, Carlo, Krüger, Klaus, Cantagrel, Alain, Abad Hernández, Miguel Angel, Freudensprung, Ulrich, Farouk Rezk, Mourad, Addison, Janet
Published in Clinical and experimental rheumatology (01.03.2021)
Published in Clinical and experimental rheumatology (01.03.2021)
Get more information
Journal Article
P637 PERFUSE: A french non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; An interim analysis
Bouhnik, Y, Fautrel, B, Desjeux, G, Freudensprung, U, Brigui, A, Addison, J
Published in Journal of Crohn's and colitis (15.01.2020)
Published in Journal of Crohn's and colitis (15.01.2020)
Get full text
Journal Article
P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
Young, D, Freudensprung, U, Harris, C, Harris, R, Harvey, J, Addison, J, Latter, S, Cummings, F
Published in Journal of Crohn's and colitis (15.01.2020)
Published in Journal of Crohn's and colitis (15.01.2020)
Get full text
Journal Article
361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC)
Andersson, M., Lopez-Vega, J.M., Petit, T., Zamagni, C., Freudensprung, U., Robb, S., Restuccia, E., Perez, E.A.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Interim Safety and Efficacy of Pertuzumab, Trastuzumab and Vinorelbine for First-Line (1L) Treatment of Patients (Pts) with Her2-Positive Locally Advanced or Metastatic Breast Cancer (Mbc)
Andersson, M., Lopez-Vega, J.M., Petit, T., Zamagni, C., Freudensprung, U., Robb, S., Restuccia, E., Perez, E.A.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
PERFUSE : étude de cohorte prospective/retrospective non-interventionnelle de patients naïfs d’infliximab ou en transition, recevant le biosimilaire SB2 d’infliximab : analyse à 12 mois
Fautrel, B., Bouhnik, Y., Dougados, M., Freudensprung, U., Addison, J.
Published in Revue du rhumatisme (Ed. française : 1993) (01.12.2021)
Published in Revue du rhumatisme (Ed. française : 1993) (01.12.2021)
Get full text
Journal Article
352OEFFICACY AND SAFETY OF MAINTENANCE BEVACIZUMAB (BEV) WITH OR WITHOUT CAPECITABINE (CAP) AFTER INITIAL FIRST-LINE BEV PLUS DOCETAXEL (DOC) FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): IMELDA RANDOMISED PHASE III TRIAL
Gligorov, J., Doval, D., Bines, J., Jiang, Z., Alba, E., Cortes, P., Srock, S., de Ducla, S., Freudensprung, U., Mustacchi, G.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer (Mbc): Imelda Randomised Phase III Trial
Gligorov, J., Doval, D., Bines, J., Jiang, Z., Alba, E., Cortes, P., Srock, S., de Ducla, S., Freudensprung, U., Mustacchi, G.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
Perez, EA, López-Vega, JM, Del Mastro, L, Petit, T, Zamagni, C, Freudensprung, U, Bastière-Truchot, L, Walker, R, Andersson, M
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of the IMELDA Trial
Gligorov, J., Alba-Conejo, E., Bines, J., Cortes, P.A., Doval, D.C., Jiang, Z., Freudensprung, U., Mustacchi, G.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article